Immunosupressants are an effective in controlling ocular inflammation caused by severe or steroid-resistant autoimmune disease, according to study results published online ahead of print by Acta Ophthalmologica.
Immunosupressants are an effective in controlling ocular inflammation caused by severe or steroid-resistant autoimmune disease, according to study results published online ahead of print by Acta Ophthalmologica.
Paolo Mora, MD of the University of Parma, Italy and colleagues conducted a prospective, non-randomized study of patients with ocular inflammation (n=76; eyes, n=121) who, after 9±2 months of non-response to monotherapy, switched to a combined immunosuppressive treatment (IST) protocol in which all treatments (including steroids) were administered discontinuously for 43±15 months.
Complete inflammation control was achieved in 86% of patients; the rate of inflammatory events per patient was 0.78±1.13 in the first year of treatment, and the rare continued to decrease throughout the follow-up period. Mean best-corrected visual acuity (BCVA) increased to 0.24 logMAR after follow-up from 0.31 logMAR at baseline. Despite these visual improvements, patients' blood pressure and uric acid blood levels worsened significantly during the study period.
The researchers concluded that IST offers long-term improvements in the rate of inflammatory events and decreases the need for steroid treatment.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.